4.5 Article

Mutational epitope analysis of Pru av 1 and Api g 1, the major allergens of cherry (Prunus avium) and celery (Apium graveolens):: correlating IgE reactivity with three-dimensional structure

Journal

BIOCHEMICAL JOURNAL
Volume 376, Issue -, Pages 97-107

Publisher

PORTLAND PRESS LTD
DOI: 10.1042/BJ20031057

Keywords

allergen structure; allergy; cross-reactivity; hypoallergenic mutants; IgE-epitope analysis

Ask authors/readers for more resources

Birch pollinosis is often accompanied by adverse reactions to food due to pollen-allergen specific IgE cross-reacting with homologous food allergens. The tertiary structure of Pru av 1, the major cherry (Prunus avium) allergen, for example, is nearly identical with Bet v 1, the major birch (Betula verrucosa) pollen allergen. In order to define cross-reactive IgE epitopes, we generated and analysed mutants of Pru av 1 and Api g 1.0101, the major celery (Apium graveolens) allergen, by immunoblotting, EAST (enzyme allergosorbent test), CD and NMR spectroscopy. The mutation of Glu(45) to Trp(45) in the P-loop region, a known IgE epitope of Bet v 1, significantly reduced IgE binding to Pru av I in a subgroup of cherry-allergic patients. The backbone conformation of Pru av 1 wild-type is conserved in the three-dimensional structure of Pru av 1 Trp(45), demonstrating that the side chain of Glu(45) is involved in a cross-reactive IgE epitope. Accordingly, for a subgroup of celery-allergic patients, IgE binding to the homologous celery allergen Api g 1.0101 was enhanced by the mutation of Lys(44) to Glu. The almost complete loss of IgE reactivity to the Pru av 1 Pro(112) mutant is due to disruption of its tertiary structure. Neither the mutation Ala(112) nor deletion of the C-terminal residues 155-159 influenced IgE binding to Pru av 1. In conclusion, the structure of the P-loop partially explains the cross-reactivity pattern, and modulation of IgE-binding by site-directed mutagenesis is a promising approach to develop hypo-allergenic variants for patient-tailored specific immunotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available